This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jou, Y.-S. Articles by Chen, P.-J. Search for Related Content PubMed PubMed Citation Articles by Jou, Y.-S. Articles by Chen, P.-J.

Clustering of Minimal Deleted Regions Reveals Distinct Genetic Pathways of Human Hepatocellular Carcinoma

¹ Division of Molecular and Genomic Medicines and ² Division of Biostatistics and Bioinformatics, National Health Research Institute; and ³ Hepatitis Research Center, Department of Internal Medicine, National Taiwan University Hospital, Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan

Systematic scan and statistical analysis of loss of heterozygosity (LOH) has been widely used to define chromosomal aberrations in various cancers for cloning of tumor suppressor genes and for development of prognostic markers. However, the establishment of novel strategies is needed, so that the nonrandom but heterogeneous chromosomal aberration data could provide significant insights into our understanding of molecular pathogenesis of cancers. After comprehensive allelotyping of recurrent allelic losses with 441 highly informative microsatellite markers and overlapping LOH regions on human hepatocellular carcinoma (HCC) chromosomes, 33 minimal deleted regions (MDRs) were revealed. Five and 15 of the 33 MDRs have physical intervals in less than 5 and 10 Mb, respectively, with the smallest MDR9p1 of 2.2 Mb located at 9p21.3-p21.2. Statistical and Kaplan-Meier survival analysis revealed a significant association between the loss of MDR15q1 (15q21.1-q22.2) and the HCC patient survival (adjusted P = 0.033). After cluster analysis of 33 MDRs that represented LOH profiles of each HCC tissue based on clinicopathological features and p53 mutations, two major genetic pathways, low-stage and advanced-stage HCC, were uncovered based on high concordance of MDR clusters. We propose that the definition of genome-wide MDRs on the cancer genome not only narrows down the location of existing tumor suppressor genes to facilitate positional candidate cloning and develop potential prognostic markers after statistical association of MDRs with clinicopathological features but also dissects genetic interactions and pathways of chromosomal aberrations in tumorigenesis.

This article has been cited by other articles:

				W. Xue, A. Krasnitz, R. Lucito, R. Sordella, L. VanAelst, C. Cordon-Cardo, S. Singer, F. Kuehnel, M. Wigler, S. Powers, et al. DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma Genes & Dev., June 1, 2008; 22(11): 1439 - 1444. [Abstract] [Full Text] [PDF]

				M. Katzenellenbogen, L. Mizrahi, O. Pappo, N. Klopstock, D. Olam, J. Jacob-Hirsch, N. Amariglio, G. Rechavi, E. Domany, E. Galun, et al. Molecular Mechanisms of Liver Carcinogenesis in the Mdr2-Knockout Mice Mol. Cancer Res., November 1, 2007; 5(11): 1159 - 1170. [Abstract] [Full Text] [PDF]

				R. Huijsmans, J. Damen, H. van der Linden, and M. Hermans Single Nucleotide Polymorphism Profiling Assay to Confirm the Identity of Human Tissues J. Mol. Diagn., April 1, 2007; 9(2): 205 - 213. [Abstract] [Full Text] [PDF]

				W.-H. Su, C.-C. Chao, S.-H. Yeh, D.-S. Chen, P.-J. Chen, and Y.-S. Jou OncoDB.HCC: an integrated oncogenomic database of hepatocellular carcinoma revealed aberrant cancer target genes and loci Nucleic Acids Res., January 12, 2007; 35(suppl_1): D727 - D731. [Abstract] [Full Text] [PDF]

				C. W. Fong, M.-S. Chua, A. B. McKie, S. H. M. Ling, V. Mason, R. Li, P. Yusoff, T. L. Lo, H. Y. Leung, S. K.S. So, et al. Sprouty 2, an Inhibitor of Mitogen-Activated Protein Kinase Signaling, Is Down-Regulated in Hepatocellular Carcinoma Cancer Res., February 15, 2006; 66(4): 2048 - 2058. [Abstract] [Full Text] [PDF]

				S.-H. Yeh, D.-C. Wu, C.-Y. Tsai, T.-J. Kuo, W.-C. Yu, Y.-S. Chang, C.-L. Chen, C.-F. Chang, D.-S. Chen, and P.-J. Chen Genetic Characterization of Fas-Associated Phosphatase-1 as a Putative Tumor Suppressor Gene on Chromosome 4q21.3 in Hepatocellular Carcinoma Clin. Cancer Res., February 15, 2006; 12(4): 1097 - 1108. [Abstract] [Full Text] [PDF]

				Y.-H. Chang, W.-H. Su, T.-C. Lee, H.-F. S. Sun, C.-H. Chen, W.-H. Pan, S.-F. Tsai, and Y.-S. Jou TPMD: a database and resources of microsatellite marker genotyped in Taiwanese populations Nucleic Acids Res., January 1, 2005; 33(suppl_1): D174 - D177. [Abstract] [Full Text] [PDF]